Along with the available FDA-authorized treatments, the DMD drug-development pipeline features additional exon-skipping therapies, nonsense mutation readthroughs, as well as gene therapies, which introduce a miniature version of the dystrophin that can rescue muscular function likened to Becker muscular dystrophy, progressing through phase trials for FDA authorization [6,34,35,36,37,38,39]. This evidence concerns the gene DMD and Becker muscular dystrophy.